Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: Doug who wrote (1592)	8/16/1999 2:25:00 PM
From: Henry Niman	Respond to of 1722

My expertise is really more on the science side and I heard pieces of the Michael Waldholz report on COX-2 Inhibitors applications for colon cancer. Sounded pretty promising, which of course would be a major plus for MTC, PFE, and MRK. However, MRK's pipeline looks particularly vulnerable and the colon data is only in patients whose colon cancer is related to strong genetic factors.

To: Doug who wrote (1592)	8/16/1999 3:12:00 PM
From: Henry Niman	Respond to of 1722

Just had a chance to review the tape on the Waldholtz report. Sounded pretty promising. MTC's Searle has already applied to FDA for preventing polyps in genetically predisposed individuals and MTC, MRK, and the NCI are planning large prevention trials netcognizance.com netcognizance.com